
The FDA advisory panel has recommended the approval of a monoclonal antibody shot called Beyfortus to prevent respiratory syncytial virus (RSV) in infants and vulnerable toddlers. RSV is a leading cause of death among infants and toddlers globally. The panel unanimously voted in favor of giving the treatment to infants during their first RSV season and voted 19-2 for children up to 24 months old who remain at risk. Up to 80,000 children under 5 are hospitalized with RSV in the United States each year, resulting in up to 300 deaths. The CDC is expected to review the use of these treatments and provide guidance to healthcare providers soon.
Like
Save
Share